Goal Attainment Scaling for Depression: Validation of the Japanese GAS-D Tool in Patients with Major Depressive Disorder
Masaki Kato,Toshiaki Kikuchi,Koichiro Watanabe,Tomiki Sumiyoshi,Yoshiya Moriguchi,Daniel Oudin Åström,Michael Cronquist Christensen
DOI: https://doi.org/10.2147/ndt.s441382
IF: 2.989
2024-01-19
Neuropsychiatric Disease and Treatment
Abstract:Masaki Kato, 1 Toshiaki Kikuchi, 2 Koichiro Watanabe, 3 Tomiki Sumiyoshi, 4 Yoshiya Moriguchi, 5 Daniel Oudin Åström, 6 Michael Cronquist Christensen 6 1 Department of Neuropsychiatry, Kansai Medical University, Osaka, Japan; 2 Department of Neuropsychiatry, Keio University School of Medicine, Department of Neuropsychiatry, Tokyo, Japan; 3 Department of Neuropsychiatry, Kyorin University School of Medicine, Tokyo, Japan; 4 Department of Preventive Intervention for Psychiatric Disorders, National Institute of Mental Health, National Center of Neurology and Psychiatry, Tokyo, Japan; 5 Lundbeck Japan K.K, Tokyo, Japan; 6 H. Lundbeck A/S, Valby, Denmark Correspondence: Yoshiya Moriguchi, Medical Affairs, Lundbeck Japan, K.K, Kamiyacho Prime Place 8F, 4-1-17 Toranomon, Minato-ku, Tokyo, 105-0001, Japan, Email Purpose: Goal attainment scaling (GAS) has been proposed as a person-centric, semi-quantitative measure that assimilates achievement of individually set goals into a single standardized "goal attainment score" that can be compared at the population level. We aimed to examine the reliability and validity of the Japanese version of the GAS for depression (GAS-D) tool in assessing goal attainment in people living with major depressive disorder (MDD). Patients and Methods: This was a prespecified analysis of a prospective, 24-week, multicenter, observational cohort study of employed Japanese outpatients with MDD initiating treatment with vortioxetine according to the Japanese label (JRCT1031210200). Participants were assessed using the Japanese version of the GAS-D and other clinical rating scales at baseline and Weeks 8, 12 and 24. Results: Goal attainment was significantly associated with symptom severity as assessed by the Montgomery–Åsberg Depression Rating Scale (MADRS) scale, confirming convergent validity. In particular, GAS-D scores were significantly related to MADRS total score at Weeks 12 and 24, indicating that improvements in overall symptom severity with vortioxetine treatment were likely to be reflected in the achievement of individualized treatment goals. With an intraclass correlation coefficient of 0.67 (95% CI 0.45– 0.82), the GAS-D also showed moderate test–retest reliability between Weeks 8 and 12 while proving independent of demographic characteristics. Conclusion: The results of this open-label study support the use of the GAS-D as a valid and sensitive outcome measure in the assessment of treatment response in MDD. Keywords: major depressive disorder, goal attainment scaling, goal setting, validation, vortioxetine Recovery from depression is often a complex, personal journey and depends on several factors such as health beliefs, baseline clinical severity and functioning, as well as medication and treatment adequacy. 1,2 Currently, the concept of recovery is clinical, referring to recovery from psychiatric symptoms, 3,4 and the most commonly used assessment tools, such as the Montgomery–Åsberg Depression Rating Scale (MADRS), focus only on symptom severity. 5 Even functional rating scales such as the Sheehan Disability Scale (SDS) do not address what is meaningful to patients. Although both patients' and clinicians' aim for "treatment success", their definitions of remission and how remission may be measured may not be equivalent. 6 Indeed, people with major depressive disorder (MDD) often have their own definitions of personal recovery, which may not always align with the physician perspective. 7,8 In one survey evaluating priorities for depression treatment, patients placed more importance on the restoration of positive affect, while the clinicians focused on alleviation of depressive symptoms. 9 Given the variations in how treatment success may be defined, flexible measures that consider the patient's unique perspective on their own condition are important. Goal attainment scaling (GAS) has been proposed as a person-centric, semi-quantitative measure that assimilates achievement of individually set goals into a single standardized "goal attainment score" that can be compared at the population level. Originally developed in the context of evaluating the effectiveness of community mental health programs, 10 a version has been developed for use in MDD (GAS-D). 11–13 The GAS-D tool leverages the collaborative process of goal setting (as an integral part of shared decision-making) and allows for a measurement of overall treatment effectiveness that is meaningful to each individual patient. The GAS-D has been used as a primary outcome measure of the effectiveness of vortioxetine in two clinical studies. -Abstract Truncated-
psychiatry,clinical neurology